Novel agents for treating allergic diseases
CA 2337859 A1 · Owner: Fujisawa, Tetsunori · Inventors: Tobetto, Kenji; Matsuo, Tetsu; Fujisawa, Tetsunori
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Drugs characterized by containing hydroxamic acid derivatives as the active ingredient which are efficacious in treating and/or preventing allergies in , particular, type I and/or type II allergies etc. These drugs exert , therapeutic and/or preventive effects on inflammation rhinitis, conjunctivitis, bronchial asthma atopic dermatitis (dermatitis, enteritis etc.) and allergic digestive inflammation. Use of these drugs achieves the effects of: (A) inhibiting the proliferation of colonies of blood cells (lymphocytes, etc.) in an affected part; and/or (B) relieving inflammation caused by the migration, infiltration, accumulation etc. of blood cells , (lymphocytes, etc.) into an affected …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 16, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 16, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 16, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.